Key Points
-
Pneumatic dilation has been recommended as the preferred first-line therapy for type I and type II achalasia, especially in patients >45 years of age
-
Heller myotomy is the treatment of choice for young patients with achalasia, and in type III achalasia
-
Some patients with oesophageal hypercontractility disorders might respond to botulinum toxin injection
-
Ongoing studies are evaluating the role of peroral endoscopic myotomy in the management of achalasia and oesophageal hypercontractility disorders
-
Dysphagia in patients with oesophageal hypocontractility is challenging, and therapies with proven efficacy are lacking
Abstract
High-resolution manometry enables the categorization of patients with oesophageal dysphagia caused by oesophageal motility disorders into diagnostic categories according to the Chicago Classification. This Review provides an overview of the literature concerning treatment options for patients with dysphagia associated with achalasia, hypercontractile disorders and hypocontractility disorders of the oesophagus. In achalasia, pharmacotherapy and botulinum toxin are less effective than pneumatic dilation or surgical Heller myotomy, which had comparable efficacy in the largest controlled trial to date. Peroral endoscopic myotomy is a novel therapeutic modality that is currently being evaluated in controlled trials versus pneumatic dilation or surgical myotomy. A variety of medical treatments have been evaluated in hypermotility disorders, but only botulinum toxin injection yielded favourable results in a single controlled trial. Few studies have addressed the treatment of dysphagia in patients with oesophageal hypomotility. A variety of prokinetic agents have been studied, but there is no evidence of clinically relevant efficacy from controlled trials.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Bredenoord, A. J. et al. International High Resolution Manometry Working Group. Chicago classification criteria of esophageal motility disorders defined in high resolution esophageal pressure topography. Neurogastroenterol. Motil. 24 (Suppl. 1), 57–65 (2012).
Stein, H. J. & DeMeester, T. R. Indications, technique, and clinical use of ambulatory 24-hour esophageal motility monitoring in a surgical practice. Ann. Surg. 217, 128–137 (1993).
Kindt, S. & Tack, J. Pathophysiology of noncardiac chest pain: not only acid. Dis. Mon. 54, 615–626 (2008).
Zerbib, F. & Omari, T. Oesophageal dysphagia: manifestations and diagnosis. Nat. Rev. Gastroenterol. Hepatol. http://dx.doi.org/10.1038/nrgastro.2014.195.
Boeckxstaens, G. E., Tack, J. & Zaninotto, G. Achalasia: pneumatic dilation or laparoscopic heller myotomy? J. Gastrointest. Surg. 16, 1284–1285 (2012).
Christensen, J. Effects of drugs on esophageal motility. Arch. Intern. Med. 136, 532–537 (1976).
Lobis, J. B. & Fischer, R. S. Anticholinergic therapy for achalasia. A controlled study. Gastroenterology 70, 976 (1976).
Nickerson, M. & Call, L. S. Treatment of cardiospasm with adrenergic blockade. Am. J. Med. 11, 123–127 (1957).
Marzio, L. et al. Effect of cimetropium bromide on esophageal motility and transit in patients affected by primary achalasia. Dig. Dis. Sci. 39, 1389–1394 (1994).
Penagini, Bartesaghi, B., Negri, G. & Bianchi, P. A. Effect of loperamide on lower oesophageal sphincter pressure in idiopathic achalasia. Scand. J. Gastroenterol. 29, 1057–1060 (1994).
Bortolotti, M. & Labo, G. Clinical and manometric effects of nifedipine in patients with esophageal achalasia. Gastroenterology 80, 39–44 (1981).
Gelfond, M., Rozen, P. & Gilat, T. Isosorbide dinitrate and nifedipine treatment of achalasia: a clinical, manometric and radionuclide evaluation. Gastroenterology 83, 963–969 (1982).
Coccia, G., Bortolotti, M., Micheti, P. & Dodero, M. Prospective clinical and manometric study comparing pneumatic dilatation and sublingual nifedipine in the treatment of oesophageal achalasia. Gut 32, 604–606 (1991).
Traube, M., Dubovik, R., Lange, R. C. & McCallum, R. W. The role of nifedipine therapy in achalasia: results of a randomized, double-blind placebo-controlled study. Am. J. Gastroenterol. 84, 1259–1262 (1989).
Triadafilopoulos, G., Aaronson, M., Sackel, S. & Burakoff, R. Medical treatment of esophageal achalasia. Double-blind crossover study with oral nifedipine, verapamil, and placebo. Dig. Dis. Sci. 36, 260–267 (1991).
Douthwaite, A. J. Achalasia of cardia. Treatment with nitrites. Lancet 2, 353–354 (1943).
Gelfond, M., Rozen, P., Keren, S. & Gilat, T. Effect of nitrates on LOS pressure in achalasia: a potential therapeutic aid. Gut 22, 312–318 (1981).
Pasricha, P. J., Ravich, W. J., Hendrix, T. R., Sostre, S. & Kalloo, A. N. Intrasphincteric botulinum toxin for the treatment of achalasia. N. Engl. J. Med. 332, 774–778 (1995).
Campos, G. M. et al. Endoscopic and surgical treatments for achalasia: a systematic review and meta-analysis. Ann. Surg. 249, 45–57 (2009).
Enestvedt, B. K., Williams, J. L. & Sonnenberg, A. Epidemiology and practice patterns of achalasia in a large multicentre database. Aliment. Pharmacol. Ther. 33, 1209–1211 (2011).
Triadafilopoulos, G. et al. The Kagoshima consensus on esophageal achalasia. Dis. Esophagus 25, 337–348 (2012).
Wang, L., Li, Y. M. & Li, L. Meta-analysis of randomized and controlled treatment trials for achalasia. Dig. Dis. Sci. 54, 2303–2311 (2009).
Tack, J., Janssens, J. & Vantrappen, G. Non-surgical treatment of achalasia. Hepatogastroenterology 38, 493–497 (1991).
Hulselmans, M. et al. Long-term outcome of pneumatic dilation in the treatment of achalasia. Clin. Gastroenterol. Hepatol. 8, 30–35 (2010).
Vaezi, M. F., Baker, M. E., Achkar, E. & Richter, J. E. Timed barium oesophagram: better predictor of long term success after pneumatic dilation in achalasia than symptom assessment. Gut 50, 765–770 (2002).
Rohof, W. O., Hirsch, D. P., Kessing, B. F. & Boeckxstaens, G. E. Efficacy of treatment for patients with achalasia depends on the distensibility of the esophagogastric junction. Gastroenterology. 143, 328–335 (2012).
Boeckxstaens, G. E. et al. Pneumatic dilation versus laparoscopic Heller's myotomy for idiopathic achalasia. N. Engl. J. Med. 364, 1807–1816 (2011).
Pandolfino, J. E. et al. Achalasia: a new clinically relevant classification by high-resolution manometry. Gastroenterology 135, 1526–1533 (2008).
Rohof, W. O. et al. Outcomes of treatment for achalasia depend on manometric subtype. Gastroenterology 144, 718–725 (2012).
Campos, G. M. et al. Endoscopic and surgical treatments for achalasia: a systematic review and meta-analysis. Ann. Surg. 249, 45–57 (2009).
West, R. L. et al. Long term results of pneumatic dilation in achalasia followed for more than 5 years. Am. J. Gastroenterol. 97, 346–1351 (2002).
Vela, M. F. et al. The long-term efficacy of pneumatic dilatation and Heller myotomy for the treatment of achalasia. Clin. Gastroenterol. Hepatol. 4, 580–587 (2006).
Vanuytsel, T. et al. Conservative management of esophageal perforations during pneumatic dilation for idiopathic esophageal achalasia. Clin. Gastroenterol. Hepatol. 10, 142–149 (2012).
Boeckxstaens, G. E., Zaninotto, G. & Richter, J. E. Achalasia. Lancet 383, 83–93 (2014).
Ortega, J. A., Madureri, V. & Perez, L. Endoscopic myotomy in the treatment of achalasia. Gastrointest. Endosc. 26, 8–10 (1980).
Pasricha, P. J. et al. Submucosal endoscopic esophageal myotomy: a novel experimental approach for the treatment of achalasia. Endoscopy 39, 761–764 (2007).
Inoue, H. et al. Peroral endoscopic myotomy (POEM) for esophageal achalasia. Endoscopy 42, 265–271 (2010).
Bredenoord, A. J., Rosch, T. & Fockens, P. Peroral endoscopic myotomy for achalasia. Neurogastroenterol. Motil. 26, 3–12 (2014).
von Renteln, D. et al. Peroral endoscopic myotomy for the treatment of achalasia. An international prospective study. Gastroenterology 145, 309–311 (2013).
Swanstrom, L. L. et al. Long-term outcome of an endoscopic myotomy for achalasia. The POEM procedure. Ann. Surg. 256, 659–667 (2012).
von Renteln, D. et al. Peroral endoscopic myotomy for esophageal achalasia. A prospective single center study. Am. J. Gastroenterol. 107, 411–417 (2012).
Teitelbaum, E. N. et al. Symptomatic and physiologic outcomes one year after peroral esophageal myotomy (POEM) for treatment of achalasia. Surg. Endosc. 28, 3359–3365 (2014).
US National Library of Medicine. ClinicalTrials.gov[online], (2015).
US National Library of Medicine. ClinicalTrials.gov[online], (2014).
Ujiki, M. B. et al. Peroral endoscopic myotomy: a short-term comparison with the standard laparoscopic approach. Surgery 154, 893–900 (2013).
Bhayani, N. H. et al. A comparative study on comprehensive, objective outcomes of laparoscopic Heller myotomy with peroral endoscopic myotomy for esophageal achalasia. Ann. Surg. 259, 1098–1103 (2014).
Heller, E. Extramukose cardiaplastik beim chronischen cardiospasmus mit dilatation des oesophagus [German]. Mitt. Grenzgeb Med. Chir. 27141–27149 (1914).
Andreoll, N. A., Lope, L. R. & Malafai, O. Heller's myotomy: a hundred years of success! Arq. Bras. Cir. Dig. 27 1–2 (2014).
Zaaijer, J. H. Cardiospasm in the aged. Ann. Surg. 77, 615–617 (1923).
Dor, J., Humbert, P., Paoli, J. M., Miorclerc, M. & Aubert, J. Treatment of reflux by the so-called modified Heller-Nissen technique [French]. Presse Med. 75, 2563–2565 (1967).
Shimi, C., Nathason, L. K. & Cuschieri, A. Laparoscopic cardiomyotomy for achalasia. J. R. Coll. Surg. Edinb. 36, 152–154 (1991).
Pellegrini, C. et al. Thoracoscopic esophagomyotomy. Initial experience with a new approach for the treatment of achalasia. Ann. Surg. 216, 291–296 (1992).
Ancona, E. et al. Heller laparoscopic cardiomyotomy with antireflux anterior fundoplication in the treatment of esophageal achalasia. Surg. Endosc. 7, 459–461 (1993).
Wang, Y. R., Dempsey, D. T., Friedenberg, F. K. & Richter, J. E. Trends of Heller myotomy hospitalizations for achalasia in the United States, 1993–2005 Effect of surgery volume on perioperative outcomes. Am. J. Gastroenterol. 103, 2454–2464 (2008).
Salvador, R. et al. Laparoscopic Heller myotomy can be used as primary therapy for esophageal achalasia regardless of age. J. Gastrointest. Surg. 18, 106–111 (2014).
Costantini, M. et al. The laparoscopic Heller-Dor operation remains an effective treatment for esophageal achalasia at a minimum 6-year follow-up. Surg. Endosc. 19, 345–351 (2005).
Chen, Z., Bessell, J. R., Chew, A. & Watson, D. I. Laparoscopic cardiomyotomy for achalasia: clinical outcomes beyond 5 years. J. Gastrointest. Surg. 14, 594–600 (2010).
Torquati, A., Richards, W. O., Holzman, M. D. & Sharp, K. W. Laparoscopic myotomy for achalasia: predictors of successful outcome after 200 cases. Ann. Surg. 243, 587–591 (2006).
Schuchert, M. J. et al. Minimally-invasive esophagomyotomy in 200 consecutive patients: factors influencing postoperative outcomes. Ann. Thorac. Surg. 85, 1729–1734 (2008).
Zaninotto, G. et al. Four hundred laparoscopic myotomies for esophageal achalasia: a single-centre experience. Ann. Surg. 248, 986–993 (2008).
Salvador, R. et al. The preoperative manometric pattern predicts the outcome of surgical treatment for esophageal achalasia. J. Gastrointest. Surg. 14, 1635–1645 (2010).
Snyder, C. W. et al. Multiple preoperative endoscopic interventions are associated with worse outcomes after laparoscopic Heller myotomy for achalasia. J. Gastrointest. Surg. 13, 2095–2103 (2009).
Finley, C. J., Kondra, J., Clifton, J., Yee, J. & Finley, R. Factors associated with postoperative symptoms after laparoscopic Heller myotomy. Ann. Thorac. Surg. 89, 392–396 (2010).
Rosemurgy, A. S., Morton, C. A., Rosas, M., Albrink, M. & Ross, S. B. A single institution's experience with more than 500 laparoscopic Heller myotomies for achalasia. J. Am. Coll. Surg. 210, 637–645 (2010).
Portale, G. et al. Long-term outcome of laparoscopic Heller-Dor surgery for esophageal achalasia: possible detrimental role of previous endoscopic treatment. J. Gastrointest. Surg. 9, 1332–1339 (2005).
Richards, W. O. et al. Heller myotomy versus Heller myotomy with Dor fundoplication for achalasia: a prospective randomized double-blind clinical trial. Ann. Surg. 240, 405–412 (2004).
Rawlings, A. et al. Laparoscopic Dor versus Toupet fundoplication following Heller myotomy for achalasia: results of a multicenter, prospective, randomized-controlled trial. Surg. Endosc. 26, 18–26 (2012).
Rebecchi, F., Giaccone, C., Farinella, E., Campaci, R. & Morino, M. Randomized controlled trial of laparoscopic Heller myotomy plus Dor fundoplication versus Nissen fundoplication for achalasia: long-term results. Ann. Surg. 248, 1023–1030 (2008).
Kurian, A. A. et al. Partial anterior vs partial posterior fundoplication following transabdominal esophagocardiomyotomy for achalasia of the esophagus. Meta-regression of objective post-operative gastro-esophageal reflux and dysphagia. JAMA Surg. 148, 85–90 (2013).
Oelschlager, B. K., Chang, L. & Pellegrini, C. A. Improved outcome after extended gastric myotomy for achalasia. Arch. Surg. 138, 490–497 (2003).
Salvador, R. et al. Shorter myotomy on the gastric site (<2.5 cm) provides adequate relief of dysphagia in achalasia patients. Dis. Esophagus http://dx.doi.org/10.1111/dote.12226.
Yaghooobi, M. et al. Laparoscopic Heller myotomy vs pneumatic dilatation in the treatment of idiopathic achalasia: a meta-analysis of randomized, controlled trials. Gastrointest. Endosc. 78, 468–475 (2013).
Schoenberg, B. et al. Laparoscopic Heller myotomy versus endoscopic balloon dilatation for the treatment of achalasia. A network meta-analysis. Ann. Surg. 258, 943–952 (2013).
Kostic, S. et al. Pneumatic dilatation or laparoscopic myotomy in the management of newly diagnosed achalasia. World J. Surg. 31, 470–478 (2007).
Novais, P. A. & Lemme, E. M. 24-H pH monitoring patterns and clinical response after achalasia treatment with pneumatic dilatation or laparoscopic Heller myotomy. Aliment. Pharmacol. Ther. 32, 1257–1265 (2010).
Zaninotto, G. et al. Etiology, diagnosis, and treatment of failures after laparoscopic Heller myotomy for achalasia. Ann. Surg. 235, 186–192 (2002).
Loviscek, M. F. et al. Recurrent dysphagia after Heller myotomy: is esophagectomy always the answer? J. Am. Coll. Surg. 216, 736–743 (2013).
Duranceau, A., Liberman, M., Martin, J. & Ferraro, P. End-stage achalasia. Dis. Esophagus 25, 319–330 (2012).
Scherer, J. R., Kwiatek, M. A., Soper, N. J., Pandolfino, J. E. & Kahrilas, P. J. Functional esophagogastric junction obstruction with intact peristalsis: a heterogeneous syndrome sometimes akin to achalasia. J. Gastrointest. Surg. 13, 2219–2225 (2009).
Orlando, R. C. & Bozymski, E. M. Clinical and manometric effects of nitroglycerin in diffuse esophageal spasm. N. Engl. J. Med. 289, 23–25 (1973).
Swamy, N. Esophageal spasm: clinical and manometric responses to nitroglycerine and long acting nitrites. Gastroenterology 72, 23–27 (1977).
Mellow, M. H. Effect of isosorbide and hydralazine in painful primary esophageal motility disorders. Gastroenterology 83, 364–379 (1982).
Nasrallah, S. M., Tommaso, C. T., Singleton, R. T. & Backhaus, E. A. Primary esophageal motor disorders: clinical response to nifedipine. South. Med. J. 78, 312–315 (1985).
Davies, H. A., Lewis, M., Rhodes, J. & Henderson, A. Nifedipine for relief of esophageal chest pain? N. Engl. J. Med. 307, 1274 (1982).
Pimentel, M., Bonorris, G. G., Chow, E. J. & Lin, H. C. Peppermint oil improves the manometric findings in diffuse esophageal spasm. J. Clin. Gastroenterol. 3, 27–31 (2001).
Eherer, A. J. et al. Effect of sildenafil on oesophageal motor function in healthy subjects and patients with oesophageal motor disorders. Gut 50, 758–764 (2002).
Fox, M., Sweis, R., Wong, T. & Anggiansah, A. Sildenafil relieves symptoms and normalizes motility in patients with oesophageal spasm: a report of two cases. Neurogastroenterol. Motil. 19, 798–803 (2007).
Clouse, R. Y., Lustman, P. J., Eckert, T. C., Ferney, D. M. & Griffith, L. S. Low dose trazodone for symptomatic patients with esophageal contraction abnormalities. A double-blind, placebo-controlled trial. Gastroenterology 92, 1027 (1987).
Miller, L. S. et al. Treatment of chest pain in patients with noncardiac, nonreflux, nonachalasia spastic esophageal motor disorders using botulinum toxin injection into the gastroesophageal junction. Am. J. Gastroenterol. 97, 1640–1646 (2002).
Miller, L. S. et al. Treatment of symptomatic nonachalasia esophageal motor disorders with botulinum toxin injection at the lower esophageal sphincter. Dig. Dis. Sci. 41, 2025–2031 (1996).
Nebendahl, J. C. et al. Treatment of diffuse esophageal spasm with botulinum toxin: a prospective study with 6 month follow up [abstract]. Gastroenterology 116, A802 (1999).
Storr, M. et al. Treatment of symptomatic diffuse esophageal spasm by endoscopic injections of botulinum toxin: a prospective study with long-term follow-up. Gastrointest. Endosc. 54, 754–759 (2001).
Vanuytsel, T., et al. Botulinum toxin reduces dysphagia in patients with nonachalasia primary esophageal motility disorders. Clin. Gastroenterol. Hepatol. 11, 1115–1121 (2013).
Marjoux, S. et al. Fatal mediastinitis following botulinum toxin injection for esophageal spasm. Endoscopy 45 (Suppl. 2), E405–E406 (2013).
Vantrappen, G. & Hellemans, J. Treatment of achalasia and related motor disorders. Gastroenterology 79, 144–154 (1980).
Irving, J. D. et al. Management of diffuse esophageal spasm with balloon dilatation. Gastrointest Radiol. 17, 189–192 (1992).
Salvador, R., Costantini, M., Rizzetto, C. & Zaninotto, G. Diffuse esophageal spasm: the surgical approach. Dis. Esophagus 25, 311–318 (2012).
Nomura, T. et al. Thoracoscopic long myotomy in prone position to treat rapid esophageal contraction with normal latency. J. Clin. Gastroenterol. http://dx.doi.org.10.1097/MCG.0000000000000123.
Shiwaku, H. et al. Successful treatment of diffuse esophageal spasm by peroral endoscopic myotomy. Gastrointest. Endosc. 77, 149–150 (2013).
Louis, H. et al. Distal esophageal spasm treated by peroral endoscopic myotomy. Am. J. Gastroenterol. 107, 1926–1927 (2012).
Minami, H. et al. Peroral esophageal myotomy (POEM) for diffuse esophageal spasm. Endoscopy 46 (Suppl. 1) E79–E81 (2014).
Blonski, W., Vela, M. F., Freeman, J., Sharma, N. & Castell, D. O. The effect of oral buspirone, pyridostigmine, and bethanechol on esophageal function evaluated with combined multichannel esophageal impedance-manometry in healthy volunteers. J. Clin. Gastroenterol. 43, 253–260 (2009).
Agrawal, A., Hila, A., Tutuian, R., Mainie, I. & Castell, D. O. Bethanechol improves smooth muscle function in patients with severe ineffective esophageal motility. J. Clin. Gastroenterol. 41, 366–370 (2007).
Fornari, F. et al. Relevance of mild ineffective oesophageal motility (IOM) and potential pharmacological reversibility of severe IOM in patients with gastro-oesophageal reflux disease. Aliment. Pharmacol. Ther. 26, 1345–1354 (2007).
Tack, J. et al. Systematic review: cardiovascular safety profile of 5-HT4 agonists developed for gastrointestinal disorders. Aliment. Pharmacol. Ther. 35, 745–767 (2012).
Tutuian, R. et al. Effects of a 5-HT4 receptor agonist on oesophageal function and gastro-oesophageal reflux: studies using combined impedance-manometry and combined impedance-pH. Aliment. Pharmacol. Ther. 24, 155–162 (2006).
Kessing, B. F. et al. Prucalopride decreases esophageal acid exposure and accelerates gastric emptying in healthy subjects. Neurogastroenterol. Motil. 26, 1079–1086 (2014).
Di Stefano, M. et al. Effect of buspirone, a 5-HT1A receptor agonist, on esophageal motility in healthy volunteers. Dis. Esophagus 25, 470–476 (2012).
Karamanolis . et al., Beneficial effect of the 5-HT1A agonist buspirone on esophagal dysfunction associated with systemic sclerosis: a pilot study. United European Gastroenterol. J. http://dx.doi.org/10.1177/2050640614560453.
Grossi, L., Cappello, G. & Marzio, L. Effect of an acute intraluminal administration of capsaicin on oesophageal motor pattern in GORD patients with ineffective oesophageal motility. Neurogastroenterol. Motil. 18, 632–636 (2006).
Annese, V. et al. Controlled trial of botulinum toxin injection versus placebo and pneumatic dilation in achalasia. Gastroenterology 111, 1418–1424 (1996).
Vaezi, M. F. et al. Botulinum toxin versus pneumatic dilatation in the treatment of achalasia: a randomised trial. Gut 44, 231–239 (1999).
Muehldorfer, S. M. et al. Esophageal achalasia: intrasphincteric injection of botulinum toxin A versus balloon dilation. Endoscopy 31, 517–521 (1999).
Prakash, C., Freedland, K. E., Chan, M. F. & Clouse, R. E. Botulinum toxin injections for achalasia symptoms can approximate the short term efficacy of a single pneumatic dilation: a survival analysis approach. Am. J. Gastroenterol. 94, 328–333 (1999).
Mikaeli, J. Fazel, A., Montazeria, G., Yaghoobi, M. & Malekzadeh, R., Randomized controlled trial comparing botulinum toxin injection to pneumatic dilatation for the treatment of achalasia. Aliment. Pharmacol. Ther. 15, 1389–1396 (2001).
Ghoshal, U. C. et al. Randomized controlled trial of intrasphincteric botulinum toxin A injection versus balloon dilatation in treatment of achalasia cardia. Dis. Esophagus 14, 227–231 (2001).
Allescher, H. D. et al. Treatment of achalasia: botulinum toxin injection vs. pneumatic balloon dilation. A prospective study with long-term follow-up. Endoscopy 33, 1007–1017 (2001).
Bansal, R. et al. Intrasphincteric botulinum toxin versus pneumatic balloon dilation for treatment of primary achalasia. J. Clin. Gastroenterol. 36, 209–214 (2003).
Ellis, F. H. Jr. Esophagomyotomy for noncardiac chest pain resulting from diffuse esophageal spasm and related disorders. Am. J. Med. 92, 129S–131S (1992).
Eypasch, E. P., DeMeester, T. R., Klingman, R. R. & Stein, H. J. Physiologic assessment and surgical management of diffuse esophageal spasm. J. Thorac. Cardiovasc. Surg. 104, 859–868 (1992).
Filipi, C. J. & Hinder, R. A. Thorascopic esophageal myotomy—a surgical technique for achalasia diffuse esophageal spasm and “nutcracker esophagus”. Surg. Endosc. 8, 921–925 (1994).
Patti, M. G. et al. Comparison of medical and minimally invasive surgical therapy for primary esophageal motility disorders. Arch. Surg. 130, 609–615 (1995).
Nastos, D., Chen, L. Q., Ferraro, P., Taillefer, R. & Duranceau, A. C. Long myotomy with antireflux repair for esophageal spastic disorders. J. Gastrointest. Surg. 6, 713–722 (2002).
Leconte, M. et al. Functional results after extended myotomy for diffuse oesophageal spasm. Br. J. Surg. 94, 1113–1118 (2007).
Author information
Authors and Affiliations
Contributions
Both authors contributed equally to this manuscript.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Tack, J., Zaninotto, G. Therapeutic options in oesophageal dysphagia. Nat Rev Gastroenterol Hepatol 12, 332–341 (2015). https://doi.org/10.1038/nrgastro.2015.45
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrgastro.2015.45
This article is cited by
-
Neurogastroenterologische Erkrankungen und Störungen der Darm-Hirn-Achse beim geriatrischen Patienten
Der Gastroenterologe (2021)
-
Esophageal Dysphagia in the Elderly
Current Treatment Options in Gastroenterology (2019)
-
The Role of Botulinum Toxin Injections for Esophageal Motility Disorders
Current Treatment Options in Gastroenterology (2018)
-
POEM in the Treatment of Esophageal Disorders
Current Treatment Options in Gastroenterology (2018)
-
Diabetes and the Esophagus
Current Treatment Options in Gastroenterology (2017)